Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add filters

Database
Language
Document Type
Year range
1.
J Natl Cancer Inst ; 113(8): 1111-1112, 2021 08 02.
Article in English | MEDLINE | ID: covidwho-1352217
2.
J Natl Cancer Inst ; 113(4): 503-504, 2021 04 06.
Article in English | MEDLINE | ID: covidwho-1254783
3.
J Natl Cancer Inst ; 113(3): 344-345, 2021 03 01.
Article in English | MEDLINE | ID: covidwho-1123319
4.
J Natl Cancer Inst ; 113(4): 371-380, 2021 04 06.
Article in English | MEDLINE | ID: covidwho-1066370

ABSTRACT

BACKGROUND: Previous studies have indicated coronavirus disease 2019 (COVID-19) patients with cancer have a high fatality rate. METHODS: We conducted a systematic review of studies that reported fatalities in COVID-19 patients with cancer. A comprehensive meta-analysis that assessed the overall case fatality rate and associated risk factors was performed. Using individual patient data, univariate and multivariable logistic regression analyses were used to estimate odds ratios (OR) for each variable with outcomes. RESULTS: We included 15 studies with 3019 patients, of which 1628 were men; 41.0% were from the United Kingdom and Europe, followed by the United States and Canada (35.7%), and Asia (China, 23.3%). The overall case fatality rate of COVID-19 patients with cancer measured 22.4% (95% confidence interval [CI] = 17.3% to 28.0%). Univariate analysis revealed age (OR = 3.57, 95% CI = 1.80 to 7.06), male sex (OR = 2.10, 95% CI = 1.07 to 4.13), and comorbidity (OR = 2.00, 95% CI = 1.04 to 3.85) were associated with increased risk of severe events (defined as the individuals being admitted to the intensive care unit, or requiring invasive ventilation, or death). In multivariable analysis, only age greater than 65 years (OR = 3.16, 95% CI = 1.45 to 6.88) and being male (OR = 2.29, 95% CI = 1.07 to 4.87) were associated with increased risk of severe events. CONCLUSIONS: Our analysis demonstrated that COVID-19 patients with cancer have a higher fatality rate compared with that of COVID-19 patients without cancer. Age and sex appear to be risk factors associated with a poorer prognosis.


Subject(s)
COVID-19/epidemiology , Neoplasms/epidemiology , Asia/epidemiology , COVID-19/mortality , COVID-19/virology , Canada/epidemiology , Comorbidity , Europe/epidemiology , Female , Humans , Male , Neoplasms/mortality , Risk Factors , SARS-CoV-2/physiology , Survival Rate , United Kingdom/epidemiology , United States/epidemiology
SELECTION OF CITATIONS
SEARCH DETAIL